PO.MCB03.02 · 分子与细胞生物学
StarD10的磷酸化调控ErbB2介导的酒精诱导的乳腺癌进展
Phosphorylation of StarD10 regulates ErbB2-mediated alcohol-induced breast cancer progression
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
引言:乳腺癌仍是全球女性中第二常见的癌症。过量饮酒显著增加乳腺癌风险,即使适度饮酒(每天一杯)也会使风险比不饮酒者升高约10%。STAR相关脂质转移结构域蛋白10(StarD10)是一种在35-40%的原发性人乳腺癌中过表达的磷酸化蛋白,其与ErbB2信号通路相互作用以促进肿瘤生长。我们既往的研究显示,乙醇暴露导致StarD10去磷酸化并增强ErbB2表达,从而导致恶性程度和侵袭性增加。然而,StarD10作为亚细胞脂质转运体在调控ErbB2驱动信号中的机制作用仍不甚清楚。本研究利用三维乳腺癌类器官模型,探讨乙醇如何影响StarD10活性和ErbB2信号通路。
材料与方法:进行脂质覆盖实验和共免疫染色,以评估StarD10在乳腺癌细胞(MCF-7、SKBR-3和BT-474)和三维乳腺癌类器官模型(PDxO)中的脂质结合特异性。此外,对类器官进行CRISPR基因编辑,以验证预先识别的StarD10磷酸化位点的功能结果。通过Western印迹分析ErbB2调控的AKT-mTOR通路的激活。在CRISPR基因编辑的乳腺癌细胞中分析细胞活力和迁移。
结果:在乙醇存在下,乳腺癌细胞(MCF-7、SKBR-3、BT-474)和乳腺癌类器官(PDxO)中观察到StarD10磷酸化的显著降低。脂质覆盖实验显示StarD10与多种磷酸肌醇相互作用,包括PI(3)P、PI(4)P、PI(5)P、PI(3,4)P₂、PI(4,5)P₂和PI(3,4,5)P₃。共免疫染色进一步证明乙醇诱导StarD10与PIP2/PIP3之间相互作用增加。通过CRISPR介导的基因编辑抑制PP2A活性可阻止乙醇诱导的StarD10去磷酸化以及ErbB2介导的AKT-mTOR通路,表明这些磷酸酶在类器官模型中作为StarD10功能的正向调节因子。此外,与乙醇处理的细胞相比,PP2A基因编辑显著降低细胞活力和迁移,提示PP2A介导的StarD10去磷酸化在促进乙醇诱导的乳腺癌细胞侵袭性中起关键作用。
结论:我们的发现表明,乙醇通过导致StarD10在T288残基处的去磷酸化来促进乳腺癌进展。利用类器官模型,我们证明PP2A磷酸酶正向调控StarD10活性。靶向StarD10的磷酸化通路可能作为一种潜在的治疗策略,以减少酒精相关的乳腺癌进展。
查看英文原文 English abstract
Introduction: Breast cancer remains the second most common cancer among women worldwide. Excessive alcohol consumption significantly increases breast cancer risk, with even moderate drinking (one drink per day) raising the risk by about 10% compared to non-drinkers. STAR-related lipid transfer domain-containing protein 10 (StarD10), a phosphoprotein overexpressed in 35-40% of primary human breast cancers, interacts with the ErbB2 signaling pathway to promote tumor growth. Our previous studies showed that ethanol exposure causes StarD10 dephosphorylation and enhances ErbB2 expression, leading to increased malignancy and aggressiveness. However, the mechanistic role of StarD10 as a subcellular lipid transporter in regulating ErbB2-driven signaling is still not well understood. This study investigates how ethanol affects StarD10 activity and the ErbB2 signaling pathway using three-dimensional breast cancer organoid models.
Materials and Methods: Lipid overlay assays and co-immunostaining were performed to assess StarD10's lipid-binding specificity in breast cancer cells (MCF-7, SKBR-3, and BT-474) and three-dimensional breast cancer organoid models (PDxO). Additionally, organoids were CRISPR gene-edited to validate the functional outcome of pre-identified StarD10 phospho-sites. Activation of the ErbB2-regulated AKT-mTOR pathway was analyzed by Western blot. Cell viability and migration were analyzed in CRISPR gene-edited breast cancer cells.
Results: A significant decrease in StarD10 phosphorylation was observed in breast cancer cells (MCF-7, SKBR-3, BT-474) and breast cancer organoids (PDxO) in the presence of ethanol. Lipid overlay assay showed that StarD10 interacts with multiple phosphoinositides, including PI(3)P, PI(4)P, PI(5)P, PI(3,4)P₂, PI(4,5)P₂, and PI(3,4,5)P₃. Co-immunostaining further demonstrated an ethanol-induced increase in the interaction between StarD10 and PIP2/PIP3. Inhibition of PP2A activity by CRISPR-mediated gene editing prevented ethanol-induced StarD10 dephosphorylation and the ErbB2-mediated AKT-mTOR pathway, indicating that these phosphatases act as positive regulators of StarD10 function in the organoid model. Moreover, PP2A gene editing significantly reduced cell viability and migration compared to ethanol-treated cells, suggesting a critical role for PP2A-mediated dephosphorylation of StarD10 in promoting ethanol-induced breast cancer cell aggressiveness.
Conclusions: Our findings show that ethanol promotes breast cancer progression by causing dephosphorylation of StarD10 at the T288 residue. Using organoid models, we demonstrate that PP2A phosphatase positively regulates StarD10 activity. Targeting the phosphorylation pathway of StarD10 may serve as a potential therapeutic strategy to reduce alcohol-related breast cancer progression.
利益披露 Disclosure
M. Dagar, None..
Y. Lim, None..
S. Chandla, None..
M. Justo, None..
N. Mavela, None..
K. Ramani, None..
M. Tomasi, None.